Adalank

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

 

 

Qhia koj txoj kev hlub

Adalank is a synthetic peptide analogue of selank, with targeted chemical alteration.

The peptide is designed as a derivative ntawm nootropic drug Selank, with the addition of an acetylated N-terminal function that enhances its adamantane-like sterically-constraining structure.

This modification acts as a powerful synergistic potentiator of the anxiolytic – nootropic compound Selank.

It circumvents Selank’s poor ntshav-hlwb barrier (BBB) penetration, thereby increasing the central nervous system activity of Adalank significantly.

The addition of an acetyl group eliminates the positive charge of the N-terminal free amino group and decreases the net charge of the peptide.

This physicochemical adjustment optimizes the isoelectric point and surface properties of Adalank, reducing non-specific electrostatic interactions.

Raws li qhov tshwm sim, the drug molecule crosses the blood–brain barrier more easily and reaches the central nervous system.

Tsis tas li ntawd xwb, acetylation protects Adalank from exopeptidase degradation and significantly increases its in vivo half-life.

This provides the advantage of prolonged therapeutic blood levels and reduces frequent dosing.

The inclusion of adamantane creates a stable “conformation core” in the Adalank peptide.

This imparts a fixed spatial orientation to the initially flexible linear peptide, promoting the stereochemical conformation necessary for biological activity even in its unbound state.

This greatly improves Adalank’s ability to cross the blood-brain barrier.

In addition, Adalank exhibits certain immunomodulatory effects.

Ib ntus

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS Nr

/

Molecular Formula

C46H75N13O10

Molecular Luj

970.19

Research Of Adalank:

1.Mechanism of Action

Efficiency-wise, Adalank’s rigid structure more closely corresponds to the allosteric modulation site of the GABA_A receptor alpha subunit, imparting stronger anxiolytic effects.

Ntxiv mus, the adamantane moiety enables hydrophobic interactions in the NMDA receptor channel area to moderate calcium influx and protect against excitotoxic injury.

This property has the potential for neuroprotection in models of ischemic brain injury and post-traumatic stress disorder (PTSD).

2.Anxiolytic Effects

As an optimized derivative of Selank, Adalank maintains a high-affinity interaction with the benzodiazepine site on the GABA_A receptor α-subunit.

Txawm li cas los, the N-terminal acetylation and adamantane scaffold shift the binding mode from “flexible induced fit” to “rigid precise docking”.

This enhances GABAergic inhibitory neurotransmission, promoting chloride influx and rapid reduction of activity in hyperactive amygdala-prefrontal cortex neural circuits.

In contrast to benzodiazepines, Adalank shows high receptor subtype selectivity, enabling sustained anxiolytic effects without the sedation, muscle relaxation, or addiction potential associated with traditional drugs.

Its therapeutic index yog 3 rau 5 times wider, supporting long-term management of generalized anxiety disorder and situational anxiety disorders.

3.Cognitive Enhancement and Memory Improvement

Adalank effectively inhibits the activation of the NF-κB inflammatory pathway and increases BDNF mRNA expression by 50%-80% in the hippocampus.

This leads to activation of downstream Akt/CREB qhia txoj kev, facilitating LTP induction and maintenance.

It significantly improves memory retention in passive avoidance tests, enhances spatial learning in the Morris dej maze, and counteracts scopolamine-induced cholinergic damage.

Preclinical data indicate that Adalank reduces working memory errors by 40%-60% and mitigates natural memory decline in aged animals, suggesting applicability in learning disorders, mild cognitive impairment, and age-related memory decline.

4.Cov teebmeem Neuroprotective

The adamantane structure in Adalank mimics the action of memantine, acting as a non-competitive NMDA receptor antagonist that causes voltage-dependent blockade of open channels and physiological regulation of calcium influx.

It reduces pathological Ca²⁺ influx by 60–70% without impairing physiological synaptic Ca²⁺ signaling, achieving a selective neuroprotective profile without disrupting normal function.

Yog li, preclinical studies highlight Adalank’s significant translational potential for early intervention in acute stroke, spinal cord injury, thiab Cov kab mob neurodegenerative.

COA

HPLC

MS

(1) Peb xav, C. R.; Dawb, C. M. Sedative-Hypnotic Agents Uas cuam tshuam Gamma-Aminobutyric Acid Receptors: Tsom ntsoov rau Flunitrazepam, Gamma-Hydroxybutyric Acid, Phenibut, thiab Selank. J Clin Pharmacol 2021, 61 Suppl 2, S114-S128. DOI: 10.1002/jcph.1922 From NLM M

(2) Cov pluag, A.; Kolomin, T.; Andreeva, L.; Bondarenko, E.; Myasoedov, N.; Slominsky, P.; Shadrina, M. Peptide Selank Txhim kho qhov cuam tshuam ntawm Diazepam hauv kev txo qis kev ntxhov siab nyob rau hauv Unpredictable Chronic Mild Stress Conditions nyob rau hauv nas.. Behav Neurol 2017, 2017, 50910

(3) Pin, L. G.; Nadorova, A. V.; Antipova, T. A.; Kruglov, S. V.; Kudrin, V. S.; Durnev, A. D. Selank, Peptide Analogue ntawm Tuftsin, Tiv thaiv Ethanol-Induced Memory Impairment los ntawm Regulating BDNF Cov Ntsiab Lus hauv Hippocampus thiab Prefrontal Cortex

(4) Pin, L. G.; Nadorova, A. V.; Seredenin, S. B. Selank Inhibits Ethanol-Induced Hyperlocomotion thiab Manifestation of Behavioral Sensitization hauv DBA/2 nas.. Bull Exp Biol Med 2016, 162 (1), 56-59. DOI: 10.1007/s10517-016-3544-6 Los ntawm NLM Medline.

(5) Nqi, N. V.; Sokolov, O.; Gabaeva, M. V.; Grivennikov, Kuv. A.; Andreeva, L. A.; Miasoedov, N. F.; Zozulia, A. A. [Semax thiab selank inhibit qhov enkephalin-degrading enzymes los ntawm tib neeg cov ntshav]]. Bioorg Khim 2001, 27 (3), 180-183. DOI: 10.1023/ib:10113730028

(6) kuv tsis paub, G. G.; Teleshova, E. S.; Bochkarev, V. K.; Koschelev, V. V.; Syunyakov, T. S. P.3.036 Novel anxiolytic Selank: Cov txiaj ntsig ntawm Phase II kev sim tshuaj. European Neuropsychopharmacology 2005, 15, S159-S160. DOI: 10.1016/s0924-977x ib(05)80332-3.

(7) Slominsky, P. A.; Shadrina, M. Kuv.; Kolomin, T. A.; Stavrovskaya, A. V.; Filatova, E. V.; Andreeva, L. A.; Illarioshkin, S. N.; Myasoedov, N. F. Peptides semax thiab selank cuam tshuam rau tus cwj pwm ntawm nas nrog 6-OHDA induced PD-zoo li parkinsonism. Txog rau Biol Sc

(8) Sollertinskaj, T. N.; Shorokhov, M. V.; Myasoedov, N. F. Cov teebmeem cerebroprotective ntawm Semax thiab Selank hauv primates ntawm ntau hom neurosis. International Journal of Psychophysiology 2008, 69 (3). DOI: 10.1016/j.ijpsycho.2008.05.356.

Ib ntus:

ac-thr-lys-pro-arg-pro-gly-pro-Adamantane-nh2

CAS:

N/A

M.W:

970.19 g/mol

Tsev Nrhiav Whatsapp Kev pabcuam Khoom